Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2016

View Archived Issues

European Commission grants funding for development of new immunotherapy candidates

ISREC-EPFL presents novel Notch pathway inhibitor

ABBV-075 demonstrates robust antitumor activity in selected solid and hematological cancer models

OncoTherapy Science and Tella partner on neoantigen dendritic cells vaccine therapy

Mitobridge and The Salk Institute patent PPARdelta agonists

Merck & Co. discloses hypoxia-inducible factor prolyl hydroxylase inhibitors

Epigenetics Pharma reports silylated pyrimidine prodrugs

Glenmark Pharmaceuticals introduces inhibitors of S-nitrosoglutathione

Constellation Pharmaceuticals and Genentech jointly develop KDM5A inhibitors

F. Hoffmann-La Roche patent divulges CYP11B2 inhibitors

CD14 demonstrates potential as a biomarker of biliary stricture formation

FDA advisory committee votes on Sarepta's NDA for eteplirsen in DMD

Opdivo granted fifth FDA breakthrough therapy designation

U.S. launch of two PD-L1 companion diagnostics

Grant supports Chembio's development of oral fluid/saliva point-of-care diagnostic test for malaria

Recursion Pharmaceuticals and Sanofi Genzyme enter drug repurposing agreement

SIGA enrolls patients in final cohort of phase III trial of tecovirimat

Protalex reports early results from phase I/II PRTX-100 study in RA

Tesaro submits IND for TSR-022

Protea Biosciences in technology license agreement with Yale for malignant melanoma detection

FDA approves Cabometyx for advanced renal cell carcinoma

Novartis applies for approval of new indications for Ilaris in Japan

BARDA supports continued development of NewLink's Ebola vaccine candidate

Novel compound from Pfizer and iTeos targets indoleamine 2,3-dioxygenase-1 for cancer

Cocrystal Pharma begins phase Ia/Ib study of HCV drug candidate

FDA approves AbbVie's sNDA for Viekira Pak

Gilead Sciences's Descovy approved in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...